DNA-methylation and protein-biomarkers have been recognized as very useful tools for minimal invasive diagnostics. These can be detected in volumes of patient's blood or serum, thus allowing integration into pre-symptomatic screening programs. The aim of this work was to evaluate the suitability of Evalution, a microparticle based multiplexing platform from MyCartis, to investigate protein and DNA methylation based biomarkers. Assays design was based on a set of 48 colon cancer specific biomarkers targeting aberrantly methylated DNA, identified and validated previously by AIT. Aiming multiplexed analyses of DNA-methylation markers upon PCR amplification from patient samples by microparticle based hybridization, PCR assays were qualified according MIQE guidelines. Then hybridization conditions were optimised using synthetic oligonucleotides. After establishment of an optimized detection protocol, the per-experiment run time was reduced to 1 h. Further optimisation using different hybridization buffers enabled improved detection sensitivity (LOD <10nM) and reduced cross-hybridization. The second part of the thesis was a proof of principle study for autoantibody based diagnostics using the Evalution platform. Therefore an indirect immunoassay was setup; therefore auto-antibodies from human serum were bound to the antigenic proteins immobilized on microparticles and detected by a labeled secondary antibody. Coupling and detection protocols were set which demonstrated the suitability of the platform for autoantibody testing. Evalution demonstrated its ability of specific detection with short assay times by means of microfluidic channels operated in the reaction limited regime, dynamic control of assay condition and real-time read-out. In this work we could successfully confirm that this platform is a valuable alternative to other methods used for multiplexed protein detection. For DNA based assay detection the current version of the platform has to be improved.